134 related articles for article (PubMed ID: 38484218)
21. Encephalitis in a patient with hypopharynx cancer treated with immune checkpoint inhibitors and radiotherapy: a case report and review of the literature.
Kang Y; Zhen H; Ma N; Zhao H; Cao B
J Cancer Res Clin Oncol; 2023 Nov; 149(17):16239-16246. PubMed ID: 37676267
[TBL] [Abstract][Full Text] [Related]
22. Beyond T cell toxicity-Intrathecal chemokine C-X-C motif ligand indicating B cell involvement in immune-related adverse events following checkpoint inhibition: A two-case series and literature review.
Otto F; Seiberl M; Lara B; Moser T; Kleindienst W; Walter WE; Peter K; Wipfler P; Harrer A
Eur J Neurol; 2024 Mar; ():e16279. PubMed ID: 38556899
[TBL] [Abstract][Full Text] [Related]
23. Severe de novo pustular psoriasiform immune-related adverse event associated with nivolumab treatment for metastatic esophageal adenocarcinoma.
Seervai RNH; Heberton M; Cho WC; Gill P; Murphy MB; Aung PP; Nagarajan P; Torres-Cabala CA; Patel AB; Ruiz-Bañobre J; Om A; Yamamoto T; Nikolaou V; Curry JL
J Cutan Pathol; 2022 May; 49(5):472-481. PubMed ID: 34888886
[TBL] [Abstract][Full Text] [Related]
24. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
Janjigian YY; Shitara K; Moehler M; Garrido M; Salman P; Shen L; Wyrwicz L; Yamaguchi K; Skoczylas T; Campos Bragagnoli A; Liu T; Schenker M; Yanez P; Tehfe M; Kowalyszyn R; Karamouzis MV; Bruges R; Zander T; Pazo-Cid R; Hitre E; Feeney K; Cleary JM; Poulart V; Cullen D; Lei M; Xiao H; Kondo K; Li M; Ajani JA
Lancet; 2021 Jul; 398(10294):27-40. PubMed ID: 34102137
[TBL] [Abstract][Full Text] [Related]
25. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome.
Jarius S; Kleiter I; Ruprecht K; Asgari N; Pitarokoili K; Borisow N; Hümmert MW; Trebst C; Pache F; Winkelmann A; Beume LA; Ringelstein M; Stich O; Aktas O; Korporal-Kuhnke M; Schwarz A; Lukas C; Haas J; Fechner K; Buttmann M; Bellmann-Strobl J; Zimmermann H; Brandt AU; Franciotta D; Schanda K; Paul F; Reindl M; Wildemann B;
J Neuroinflammation; 2016 Nov; 13(1):281. PubMed ID: 27802825
[TBL] [Abstract][Full Text] [Related]
26. Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer.
Williams TJ; Benavides DR; Patrice KA; Dalmau JO; de Ávila AL; Le DT; Lipson EJ; Probasco JC; Mowry EM
JAMA Neurol; 2016 Aug; 73(8):928-33. PubMed ID: 27271951
[TBL] [Abstract][Full Text] [Related]
27. Immune Checkpoint Inhibitor-Mediated Myasthenia Gravis.
Ho AK; Cooksley T
J Emerg Med; 2020 Oct; 59(4):561-562. PubMed ID: 32565169
[TBL] [Abstract][Full Text] [Related]
28. Identification of SKOR2 IgG as a novel biomarker of paraneoplastic neurologic syndrome.
Rezk M; Pittock SJ; Kapadia RK; Knight AM; Guo Y; Gupta P; LaFrance-Corey RG; Zekeridou A; McKeon A; Dasari S; Mills JR; Dubey D
Front Immunol; 2023; 14():1243946. PubMed ID: 37795104
[TBL] [Abstract][Full Text] [Related]
29. Phosphodiesterase 10A IgG: A novel biomarker of paraneoplastic neurologic autoimmunity.
Zekeridou A; Kryzer T; Guo Y; Hassan A; Lennon V; Lucchinetti CF; Pittock S; McKeon A
Neurology; 2019 Aug; 93(8):e815-e822. PubMed ID: 31315972
[TBL] [Abstract][Full Text] [Related]
30. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.
Kelly RJ; Ajani JA; Kuzdzal J; Zander T; Van Cutsem E; Piessen G; Mendez G; Feliciano J; Motoyama S; Lièvre A; Uronis H; Elimova E; Grootscholten C; Geboes K; Zafar S; Snow S; Ko AH; Feeney K; Schenker M; Kocon P; Zhang J; Zhu L; Lei M; Singh P; Kondo K; Cleary JM; Moehler M;
N Engl J Med; 2021 Apr; 384(13):1191-1203. PubMed ID: 33789008
[TBL] [Abstract][Full Text] [Related]
31. A case series of PD-1 inhibitor-associated paraneoplastic neurologic syndromes.
Gill A; Perez MA; Perrone CM; Bae CJ; Pruitt AA; Lancaster E
J Neuroimmunol; 2019 Sep; 334():576980. PubMed ID: 31195181
[TBL] [Abstract][Full Text] [Related]
32. Nivolumab and Ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation.
Valenti-Azcarate R; Esparragosa Vazquez I; Toledano Illan C; Idoate Gastearena MA; Gállego Pérez-Larraya J
Neuromuscul Disord; 2020 Jan; 30(1):67-69. PubMed ID: 31839404
[TBL] [Abstract][Full Text] [Related]
33. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
[TBL] [Abstract][Full Text] [Related]
34. Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database.
Mikami T; Liaw B; Asada M; Niimura T; Zamami Y; Green-LaRoche D; Pai L; Levy M; Jeyapalan S
J Neurooncol; 2021 Mar; 152(1):135-144. PubMed ID: 33423151
[TBL] [Abstract][Full Text] [Related]
35. Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy.
Warner BM; Baer AN; Lipson EJ; Allen C; Hinrichs C; Rajan A; Pelayo E; Beach M; Gulley JL; Madan RA; Feliciano J; Grisius M; Long L; Powers A; Kleiner DE; Cappelli L; Alevizos I
Oncologist; 2019 Sep; 24(9):1259-1269. PubMed ID: 30996010
[TBL] [Abstract][Full Text] [Related]
36. Immunopathogenesis and proposed clinical score for identifying Kelch-like protein-11 encephalitis.
Vogrig A; Péricart S; Pinto AL; Rogemond V; Muñiz-Castrillo S; Picard G; Selton M; Mittelbronn M; Lanoiselée HM; Michenet P; Benaiteau M; Pariente J; Zéphir H; Giordana C; Montaut S; Salhi H; Bachoumas P; Montcuquet A; Letovanec I; Uro-Coste E; Honnorat J
Brain Commun; 2021; 3(3):fcab185. PubMed ID: 34557666
[TBL] [Abstract][Full Text] [Related]
37. Clinical and serological insights into paraneoplastic brachial amyotrophic diplegia.
Kherbek H; Itoh CY; Daley C; Eggers SD; Hinson S; Sarker P; Staff NP; Pittock SJ; Dubey D
J Neurol; 2024 May; ():. PubMed ID: 38772930
[TBL] [Abstract][Full Text] [Related]
38. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
39. Nivolumab-related myasthenia gravis with myositis requiring prolonged mechanical ventilation: a case report.
Saishu Y; Yoshida T; Seino Y; Nomura T
J Med Case Rep; 2022 Feb; 16(1):61. PubMed ID: 35152911
[TBL] [Abstract][Full Text] [Related]
40. Immune checkpoint-mediated myositis and myasthenia gravis: A case report and review of evaluation and management.
Kang KH; Grubb W; Sawlani K; Gibson MK; Hoimes CJ; Rogers LR; Lavertu P; Yao M
Am J Otolaryngol; 2018; 39(5):642-645. PubMed ID: 29903623
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]